ストックスクリーナーアプリを入手
44.84
4.57%
1.906
Merus N V (MRUS) 最新ニュース
Biotech Stock Boosted on Brand-New 'Buy' Rating - Schaeffers Research
The Goldman Sachs Group Initiates Coverage on Merus (NASDAQ:MRUS) - MarketBeat
Merus stock a 'buy' for Goldman, driven by peto's market potential in HNSCC - Investing.com UK
Merus initiated with a Buy at Goldman Sachs - TipRanks
Needham & Company LLC Reaffirms Buy Rating for Merus (NASDAQ:MRUS) - MarketBeat
Merus (NASDAQ:MRUS) Shares Sold by First Turn Management LLC - MarketBeat
37,426 Shares in Merus (NASDAQ:MRUS) Acquired by State of New Jersey Common Pension Fund D - Defense World
Merus is Now Oversold (MRUS) - Nasdaq
GSA Capital Partners LLP Purchases Shares of 13,502 Merus (NASDAQ:MRUS) - MarketBeat
2,054 Shares in Merus (NASDAQ:MRUS) Purchased by US Bancorp DE - Defense World
Commodore Capital LP Bolsters Stake in Merus NV - GuruFocus.com
SAMLYN CAPITAL, LLC Bolsters Stake in Merus NV - GuruFocus.com
(MRUS) Trading Report - Stock Traders Daily
Is Merus N.V. (MRUS) Top Performing European Stock Heading into 2025? - MSN
FMR LLC Bolsters Stake in Merus NV - GuruFocus.com
10 Top Performing European Stocks Heading into 2025 - Insider Monkey
Merus (NASDAQ:MRUS) Shares Bought by TimesSquare Capital Management LLC - MarketBeat
US FDA extends review of Merus' gene-targeting cancer therapy - MSN
Merus (NASDAQ:MRUS) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Merus (NASDAQ:MRUS) Receives $86.70 Consensus Price Target from Brokerages - MarketBeat
MRUSMerus N.V. Common Shares Latest Stock News & Market Updates - StockTitan
Merus to Present at Upcoming Investor Conferences - The Manila Times
Merus Receives FDA extension of PDUFA for zenocutuzumab - GlobeNewswire
FDA extends review date for Merus' cancer drug Zeno By Investing.com - Investing.com Canada
FDA extends review date for Merus' cancer drug Zeno - Investing.com India
Merus (NASDAQ:MRUS) Shares Gap DownHere's Why - MarketBeat
Merus: Petosemtamab Set Up For December 2024 Data Presentation (NASDAQ:MRUS) - Seeking Alpha
FDA extends review period for Merus's cancer drug Zeno - Investing.com India
Merus : FDA Extends Review of Cancer Drug Zenocutuzumab to February - Marketscreener.com
US FDA extends review of Merus’ gene-targeting cancer therapy - PharmaLive
Merus says FDA extended review period for cancer drug - MSN
Merus stock slips as FDA delays drug review (MRUS:NASDAQ) - Seeking Alpha
FDA extends review period for Merus's cancer drug Zeno By Investing.com - Investing.com Canada
Harbor Capital Advisors Inc. Buys New Holdings in Merus (NASDAQ:MRUS) - MarketBeat
abrdn plc Invests $4.36 Million in Merus (NASDAQ:MRUS) - MarketBeat
Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Merus sees cash runway into 2028 - MSN
Merus reports Q3 EPS ($1.46), consensus (88c) - MSN
Merus annonce ses résultats financiers pour le troisième trimestre 2024 et fait le point sur ses activités - GlobeNewswire Inc.
Merus (NASDAQ:MRUS) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Merus N.V. Reports Q3 2024 Financial Results - TipRanks
Merus falls after updated data for lung cancer therapy - MSN
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update - GlobeNewswire
Novo Holdings A S Increases Position in Merus (NASDAQ:MRUS) - MarketBeat
Merus (NASDAQ:MRUS) Coverage Initiated at UBS Group - Defense World
1.80%
0.42%
大文字化:
|
ボリューム (24 時間):